 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The company believes this matter is without merit, Natco Pharma said in a statement.

Natco Pharma, others sued in US for generic cancer drug

The other defendants named in the lawsuit were Celgene Corporation, Bristol Myers Squibb, and Breckenridge Pharmaceutical.

Natco Pharma slumps 3% over US anti-trust lawsuit

Natco Pharma announced that the Annual General Meeting (AGM) of the company will be held on 29 September 2023.

Natco Pharma to hold AGM

Natco Pharma’s objective of the acquisition is investment for bio control of pest.

Natco Pharma shares trade flat on $2 mn investment in US pesticides company

Natco Pharma Consolidated June 2023 Net Sales at Rs 1,140.50 crore, up 28.93% Y-o-Y

Natco Pharma Ltd is up for a third straight session in a row. The stock is quoting at Rs 724.3, up 1.44% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.4% on the day, quoting at 19642.65. The Sensex is at 66344.78, up 0.43%. Natco Pharma Ltd has gained around 14.73% in last one month. Meanwhile, Nifty Metal index of which Natco Pharma Ltd is a constituent, has gained around 6.06% in last one month and is currently quoting at 13945.65, up 0.88% on the day. The volume in the stock stood at 4.12 lakh shares today, compared to the daily average of 9.28 lakh shares in last one month.The PE of the stock is 20.45 based on TTM earnings ending March 23.

Natco Pharma Ltd soars 1.44%

Net Sales are expected to increase by 35.1 percent Y-o-Y (up 33.1 percent Q-o-Q) to Rs 1,195.4 crore, according to Nirmal Bang.

Natco Q1 PAT seen up 36.2% YoY to Rs 436.5 cr: Nirmal Bang

The index is likely to consolidate in the monthly F&amp;O expiry week, and if the index takes support and rebounds, then 18,700-18,900 could be the resistance area, whereas 18,500-18,450 could be the next crucial support in case of correction in coming sessions

Ten best bets for next 3-4 weeks as bulls go slow on scaling new highs

Natco Pharma has seen a big breakout of around six-week consolidation with strong volumes. The stock has also seen a crossover with 50-day EMA crossing the 200-day EMA in the week gone by, which is a positive sign.

Trade Spotlight | How you should trade in DCM Shriram, ICICI Securities, Natco Pharma

Geojit is bullish on NATCO Pharma has recommended buy rating on the stock with a target price of Rs 765 in its research report dated June 21, 2023.

Buy NATCO Pharma; target of Rs 765: Geojit

NATCO Pharma Ltd. engages in the business of pharmaceuticals with research, manufacturing and marketing of finished dosage formulations and active pharmaceutical ingredients. It operates through the following segments: Domestic Formulations, International Formulations, and Active Pharmaceutical Ingredients. The Domestic Formulations segment operates in the divisions of oncology, pharma specialties and CnD. The International Formulations segment exports its FDF products from India to several international geographies either through its local partners or directly through its subsidiaries such as in Canada and Brazil. The Active Pharmaceutical Ingredients segment is strategically important as it develops APIs for the captive consumption of many of NATCO's critical FDF products in addition to supplying to direct customers. The company was founded by Venkaiah Chowdary Nannapaneni in 1981 and is headquartered in Hyderabad, India.

Watchers	108
52-Wk Low	502.00
52-Wk High	928.00

Market Cap	156.35B
Volume (M)	417,250.00
52-Wk High	928.00
52-Wk Low	502.00

NATCOPHARM.NSE NATCO Pharma Ltd.

About

Feed

News

Sentiment

Fundamentals